QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
Free Trial
NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)
Free TAK Stock Alerts
$13.25
+0.07 (+0.53%)
(As of 01:33 PM ET)
Compare
Today's Range
$13.22
▼
$13.30
50-Day Range
$13.19
▼
$14.86
52-Week Range
$13.17
▼
$17.11
Volume
1.20 million shs
Average Volume
1.85 million shs
Market Capitalization
$41.93 billion
P/E Ratio
20.08
Dividend Yield
3.92%
Price Target
$14.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Takeda Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
5.4% Upside
$14.00 Price Target
Short Interest
Bearish
0.26% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.66mentions of Takeda Pharmaceutical in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$30 M Sold Last Quarter
Proj. Earnings Growth
-16.67%
From $1.50 to $1.25 Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.22 out of 5 stars

Medical Sector

913th out of 930 stocks

Pharmaceutical Preparations Industry

423rd out of 431 stocks

See Top Rated MarketRank™ Stocks Here
TAK stock logo

About Takeda Pharmaceutical Stock (NYSE:TAK)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Stock Price History

TAK Stock News Headlines

April 8, 2024 | businesswire.com
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
April 2, 2024 | businesswire.com
Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board
April 16, 2024 | Manward Press (Ad)
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
April 1, 2024 | finance.yahoo.com
Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO
March 28, 2024 | usnews.com
Puerto Rico Declares Dengue Epidemic as Cases Climb
March 27, 2024 | prnewswire.com
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
March 26, 2024 | businesswire.com
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
March 26, 2024 | markets.businessinsider.com
Takeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In Japan
April 16, 2024 | Manward Press (Ad)
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
March 26, 2024 | finance.yahoo.com
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
March 21, 2024 | finance.yahoo.com
The Leadership Development Group Releases Guide on Talent Management Strategies For Post-Milestone Growth
March 19, 2024 | markets.businessinsider.com
Takeda : FDA Approves SNDA For Iclusig In Adult Patients With Newly Diagnosed Ph+ ALL
March 19, 2024 | businesswire.com
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
March 18, 2024 | businesswire.com
Advanced Infusion Care (AIC) Now Offers Takeda's GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] and ARALAST® NP [Alpha1-Proteinase Inhibitor (Human)]
March 15, 2024 | finanznachrichten.de
Takeda Pharmaceuticals: Takeda's 'In Their Shoes' Program Sheds Light on IBD Challenges in South Africa
March 13, 2024 | finance.yahoo.com
Prostate Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
March 13, 2024 | finance.yahoo.com
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
March 5, 2024 | seekingalpha.com
Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds
March 5, 2024 | bizjournals.com
Five things: Takeda's big lease, more biotech cuts, Ted Williams' jersey and a basketball bandwagon
March 4, 2024 | msn.com
Takeda staying in Kendall Square
March 3, 2024 | seekingalpha.com
Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits
February 27, 2024 | msn.com
Takeda and India's Biological E. to accelerate access to dengue vaccine in endemic areas
February 27, 2024 | reuters.com
Japan's Takeda partners with India's Biological E. to boost dengue vaccine production
February 26, 2024 | businesswire.com
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
February 26, 2024 | finance.yahoo.com
Championing Rare Voices on Rare Disease Day
February 24, 2024 | benzinga.com
Evaluating Johnson & Johnson Against Peers In Pharmaceuticals Industry
February 24, 2024 | insidermonkey.com
5 Best Japanese Stocks To Buy In 2024
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/01/2024
Today
4/16/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
3/31/2025
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:TAK
CUSIP
N/A
CIK
1395064
Web
www.takeda.com
Phone
(166) 204-2111
Fax
813-3278-2268
Employees
49,095
Year Founded
1781

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$14.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+5.8%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.66
Trailing P/E Ratio
20.05
Forward P/E Ratio
8.82
P/E Growth
3.78
Net Income
$2.35 billion
Net Margins
6.90%
Pretax Margin
3.72%
Return on Equity
12.57%
Return on Assets
5.89%

Debt

Debt-to-Equity Ratio
0.64
Current Ratio
1.06
Quick Ratio
0.55

Sales & Book Value

Annual Sales
$4.17 trillion
Price / Sales
0.01
Cash Flow
$3.55 per share
Price / Cash Flow
3.73
Book Value
$14.86 per share
Price / Book
0.89

Miscellaneous

Outstanding Shares
3,164,818,000
Free Float
3,163,552,000
Market Cap
$41.87 billion
Optionable
Optionable
Beta
0.53

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Christophe Weber (Age 58)
    President, CEO & Representative Director
    Comp: $3.74M
  • Dr. Andrew S. Plump (Age 59)
    President of Research & Development and Representative Director
    Comp: $2.67M
  • Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Milano Furuta (Age 46)
    Chief Financial Officer
  • Mr. Haruhiko Hirate (Age 67)
    Member of Management Board
  • Mr. Salvatore Alesci M.D. (Age 49)
    Ph.D., Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda
    Chief Accounting Officer & Corporate Controller
  • Mr. Iwaaki Taniguchi
    Senior Vice President of Corporate Finance & Controlling Department
  • Mr. Gabriele Ricci (Age 46)
    Chief Data & Technology Officer
  • Mr. Christopher David O'Reilly
    Global Head of Investor Relations & Global Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • Takeda Pharmaceutical has a diverse portfolio of pharmaceutical products in areas such as gastroenterology, rare diseases, oncology, and neuroscience, providing revenue stability and growth potential.
  • The company has been actively engaging in collaborations and licensing agreements with various biotech and pharmaceutical companies, enhancing its research and development capabilities and potentially leading to innovative product launches.
  • Recent increase in institutional investments in Takeda Pharmaceutical, indicating confidence from major investors in the company's growth prospects.
  • Takeda Pharmaceutical's stock price has shown resilience and stability, with a market cap of $42.68 billion, indicating a strong position in the market.
  • The company's global presence and established history since 1781 provide a solid foundation for long-term growth and sustainability in the pharmaceutical industry.

Cons

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • Takeda Pharmaceutical's PEG ratio of 3.83 may indicate that the stock is overvalued compared to its earnings growth potential, potentially leading to limited upside for investors.
  • The company's debt-to-equity ratio of 0.64 suggests a moderate level of debt, which could pose risks in case of economic downturns or financial challenges.
  • Takeda Pharmaceutical's current ratio of 1.06 may indicate a lower liquidity position, which could impact the company's ability to meet short-term financial obligations.
  • The beta of 0.53 for Takeda Pharmaceutical implies lower volatility compared to the market, potentially limiting short-term trading opportunities for investors seeking higher returns.
  • Despite collaborations and licensing agreements, the competitive nature of the pharmaceutical industry poses challenges in maintaining market share and profitability, which could affect investor returns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

TAK Stock Analysis - Frequently Asked Questions

What is Takeda Pharmaceutical's stock price target for 2024?

0 analysts have issued 12 month price objectives for Takeda Pharmaceutical's shares. Their TAK share price targets range from $14.00 to $14.00. On average, they anticipate the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 5.4% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2024?

Takeda Pharmaceutical's stock was trading at $14.27 at the beginning of the year. Since then, TAK shares have decreased by 6.9% and is now trading at $13.28.
View the best growth stocks for 2024 here.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,120,000 shares, an increase of 47.6% from the March 15th total of 5,500,000 shares. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is currently 4.4 days. Approximately 0.3% of the shares of the stock are short sold.
View Takeda Pharmaceutical's Short Interest.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TAK earnings forecast.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) released its earnings results on Thursday, February, 1st. The company reported $0.51 earnings per share for the quarter. The firm had revenue of $7.52 billion for the quarter. Takeda Pharmaceutical had a trailing twelve-month return on equity of 12.57% and a net margin of 6.90%.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.52 per share and currently has a dividend yield of 3.91%. The dividend payout ratio is 78.79%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, TAK will have a dividend payout ratio of 41.60% next year. This indicates that the company will be able to sustain or increase its dividend.

What ETFs hold Takeda Pharmaceutical's stock?

ETFs with the largest weight of Takeda Pharmaceutical (NYSE:TAK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), B.A.D. Etf (BAD), First Trust International IPO ETF (FPXI) and ActivePassive International Equity ETF (APIE).Amplify Treatments, Testing and Advancements ETF (GERM).

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2023 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of 3.030-3.030 for the period. The company issued revenue guidance of $26.9 billion-$26.9 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wealth Enhancement Advisory Services LLC (0.00%), NBC Securities Inc. (0.00%), Park Avenue Securities LLC (0.00%), Ballentine Partners LLC (0.00%), &PARTNERS (0.00%) and Bruce G. Allen Investments LLC (0.00%).
View institutional ownership trends.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
This page (NYSE:TAK) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Can't believe it's happening again
Manward Press
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The “Perfect Storm” for Gold
Gold Safe Exchange
Top 5 AI Stocks to Buy for 2024
Market Moving Trends